The New York Genome Center (NYGC) welcomes Dan Avi Landau, MD, PhD, as a Core Member, Assistant Investigator.
Dr. Landau’s lab is working to discover fundamental principals in evolutionary biology and biological regulation of human cancer cells. The ultimate goal is to understand the basic dimensions that determine cancer’s evolution, in order to devise therapies that directly anticipate and address it.
“Dan Landau’s determination and wide-ranging expertise in cancer genomics will make him an invaluable member of NYGC’s faculty,” said Robert B. Darnell, NYGC’s President, CEO and Scientific Director. “His creativity, pioneering the integration of computational cancer genetics and epigenetics bases of cancer, is aimed toward an endpoint we are focused on as a team in NY—overcoming cancer by using genomic science for better patient outcomes.”
Dr. Landau grew up in Tel Aviv, Israel where he obtained his MD from Tel Aviv University. He then went on to receive his PhD from Paris Diderot University in Paris, France. His most recent position was an Instructor of Medicine at Harvard Medical School, working at the Dana Farber Cancer Institute and the Broad Institute.
“Cancer evolution is one of the foremost obstacles to cure, enabling tumors to adapt to our best therapies. My mission at the NYGC is to generate the knowledge infrastructure that will allow us to apply quantitative therapeutic engineering methods in order to purposefully control the course of this evolution, leading it towards an extinction outcome,” explains Dr. Landau.
Dr. Landau will spend time as an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology & the Department of Physiology and Biophysics at Weill Cornell Medicine in conjunction with his appointment at the New York Genome Center.
About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve people’s lives – ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University College of Physicians and Surgeons, Cornell University/Weill Cornell Medicine, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan- Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, North Shore-LIJ, The Rockefeller University, Roswell Park Cancer Institute and Stony Brook University. For more information, visit: nygenome.org.
